Dasatinib alters the metastatic phenotype of B16-OVA melanoma in vivo

Cancer Biology and Therapy

Volumn 10, Issue 7, 2010, Pages 715-727

  Fraser, Cara K ^a,f   Lousberg, Erin L ^a,f   Guerin, Leigh R ^b   Hughes, Timothy P ^a,d   Brown, Michael P ^a,e,f   Diener, Kerrilyn R ^a,f   Hayball, John D ^a,c,f  

^a HANSON INSTITUTE   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c UNIVERSITY OF ADELAIDE   (Australia)

^d Royal Adelaide Hospital ^*  (Australia)

^e ROYAL ADELAIDE HOSPITAL   (Australia)

^f UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

Fowlpox virus; Immunotherapy; Metastatic melanoma; Tyrosine kinase inhibitor

Indexed keywords

DASATINIB; ONCOLYTIC VIRUS; OVALBUMIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; FOWLPOX VIRUS; HISTOPATHOLOGY; IN VIVO STUDY; LOW DRUG DOSE; LUNG METASTASIS; MELANOMA; MELANOMA B16; METASTASIS POTENTIAL; MONOTHERAPY; MOUSE; NONHUMAN; PHENOTYPE;

ANIMALS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; FOWLPOX VIRUS; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; OVALBUMIN; PROTEIN KINASE INHIBITORS; PYRIMIDINES; THIAZOLES; TIME FACTORS;

EID: 77957595381     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.10.7.12926     Document Type: Article

References (83)

1. Komenaka I, Hoerig H, Kaufman HL. Immunotherapy for melanoma. Clin Dermatol 2004; 22:251-65.
2. st century, part 1: epidemiology, risk factors, screening, prevention and diagnosis. Mayo Clin Proc 2007; 82:364-80.
3. Kopetz S, Shah AN, Gallick GE. Src continues aging: current and future clinical directions. Clin Cancer Res 2007; 13:7232-6.
4. Summy JM, Gallick GE. Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev 2003; 22:337-58.
5. Bromann PA, Korkaya H, Courtneidge SA. The interplay between Src family kinases and receptor tyrosine kinases. Oncogene 2004; 23:7957-68. (Pubitemid 39468854)
6. Homsi J, Cubitt C, Daud A. The Src signaling pathway: a potential target in melanoma and other malignancies. Expert Opin Ther Targets 2007; 11:91-100.
7. Hsia DA, Mitra SK, Hauck CR, Streblow DN, Nelson JA, Ilic D, et al. Differential regulation of cell motility and invasion by FAK. J Cell Biol 2003; 160:753-67.
8. Playford MP, Schaller MD. The interplay between Src and integrins in normal and tumor biology. Oncogene 2004; 23:7928-46.
9. Mirmohammadsadegh A, Hassan M, Bardenheuer W, Marini A, Gustrau A, Nambiar S, et al. STAT5 phosphorylation in malignant melanoma is important for survival and is mediated through SRC and JAK1 kinases. J Invest Dermatol 2006; 126:2272-80.
10. Yu CL, Meyer DJ, Campbell GS, Larner AC, Carter-Su C, Schwartz J, et al. Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science 1995; 269:81-3.
11. Frixen UH, Behrens J, Sachs M, Eberle G, Voss B, Warda A, et al. E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells. J Cell Biol 1991; 113:173-85.
12. Fujita Y, Krause G, Scheffner M, Zechner D, Leddy HE, Behrens J, et al. Hakai, a c-Cbl-like protein, ubiquitinates and induces endocytosis of the E-cadherin complex. Nat Cell Biol 2002; 4:222-31.
13. Yeatman TJ. A renaissance for SRC. Nat Rev Cancer 2004; 4:470-80.
14. Niu G, Bowman T, Huang M, Shivers S, Reintgen D, Daud A, et al. Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene 2002; 21:7001-10.
15. Qi J, Wang J, Romanyuk O, Siu CH. Involvement of Src family kinases in N-cadherin phosphorylation and beta-catenin dissociation during transendothelial migration of melanoma cells. Mol Biol Cell 2006; 17:1261-72. (Pubitemid 43376547)
16. Takeichi M. Morphogenetic roles of classic cadherins. Curr Opin Cell Biol 1995; 7:619-27.
17. Huang J, Asawa T, Takato T, Sakai R. Cooperative roles of Fyn and cortactin in cell migration of metastatic murine melanoma. J Biol Chem 2003; 278:48367-76.
18. Wellbrock C, Weisser C, Geissinger E, Troppmair J, Schartl M. Activation of p59(Fyn) leads to melanocyte dedifferentiation by influencing MKP-1-regulated mitogen-activated protein kinase signaling. J Biol Chem 2002; 277:6443-54.
19. Loganzo F Jr, Dosik JS, Zhao Y, Vidal MJ, Nanus DM, Sudol M, et al. Elevated expression of protein tyrosine kinase c-Yes, but not c-Src, in human malignant melanoma. Oncogene 1993; 8:2637-44.
20. Marchetti D, Parikh N, Sudol M, Gallick GE. Stimulation of the protein tyrosine kinase c-Yes but not c-Src by neurotrophins in human brain-metastatic melanoma cells. Oncogene 1998; 16:3253-60.
21. Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K, et al. Discovery of N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1- yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004; 47:6658-61.
22. Deguchi Y, Kimura S, Ashihara E, Niwa T, Hodohara K, Fujiyama Y, et al. Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines. Leuk Res 2008; 32:980-3.
23. Antonescu CR, Busam KJ, Francone TD, Wong GC, Guo T, Agaram NP, et al. L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition. Int J Cancer 2007; 121:257-64.
24. Woodman SE, Trent JC, Stemke-Hale K, Lazar AJ, Pricl S, Pavan GM, et al. Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular and clinical correlates. Mol Cancer Ther 2009; 8:2079-85.
25. Buettner R, Mesa T, Vultur A, Lee F, Jove R. Inhibition of Src family kinases with dasatinib blocks migration and invasion of human melanoma cells. Mol Cancer Res 2008; 6:1766-74.
26. Eustace AJ, Crown J, Clynes M, O'Donovan N. Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines. J Transl Med 2008; 6:53.
27. + T cells. J Exp Med 2003; 198:569-80.
28. Matsushita N, Pilon-Thomas SA, Martin LM, Riker AI. Comparative methodologies of regulatory T cell depletion in a murine melanoma model. J Immunol Methods 2008; 333:167-79.
29. + T cells: a common basis between tumor immunity and autoimmunity. J Immunol 1999; 163:5211-8.
30. Takahashi T, Ibata M, Yu Z, Shikama Y, Endo Y, Miyauchi Y, et al. Rejection of intradermally injected syngeneic tumor cells from mice by specific elimination of tumor-associated macrophages with liposome-encapsulated dichloromethylene diphosphonate, followed by induction of CD11b(+)/CCR3(-)/Gr- 1(-) cells cytotoxic against the tumor cells. Cancer Immunol Immunother 2009; 58:2011-23.
31. O'Connor TJ, Fujita DJ. Differentiation of B16 murine melanoma cells is associated with an increased level of c-SRC. Melanoma Res 1995; 5:5-13.
32. Blake S, Hughes TP, Mayrhofer G, Lyons AB. The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro. Clin Immunol 2008; 127:330-9.
33. Blake SJ, Bruce Lyons A, Fraser CK, Hayball JD, Hughes TP. Dasatinib suppresses in vitro natural killer cell cytotoxicity. Blood 2008; 111:4415-6.
34. + T cells specific for viral and leukemia antigens. Exp Hematol 2008; 36:1297-308.
35. + T-cell responses and NK-cell cytolytic activity in vitro and in vivo. Exp Hematol 2009; 37:256-65.
36. Fraser CK, Lousberg EL, Kumar R, Hughes TP, Diener KR, Hayball JD. Dasatinib inhibits the secretion of TNFalpha following TLR stimulation in vitro and in vivo. Exp Hematol 2009; 37:1435-44.
37. Schade AE, Schieven GL, Townsend R, Jankowska AM, Susulic V, Zhang R, et al. Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation. Blood 2008; 111:1366-77.
38. Sillaber C, Herrmann H, Bennett K, Rix U, Baumgartner C, Bohm A, et al. Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily. Eur J Clin Invest 2009.
39. + regulatory T cells. Br J Haematol 2009; 144:195-205.
40. Hermans IF, Chong TW, Palmowski MJ, Harris AL, Cerundolo V. Synergistic effect of metronomic dosing of cyclophosphamide combined with specific antitumor immunotherapy in a murine melanoma model. Cancer Res 2003; 63:8408-13. (Pubitemid 37549496)
41. Machiels JP, Reilly RT, Emens LA, Ercolini AM, Lei RY, Weintraub D, et al. Cyclophosphamide, doxorubicin and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res 2001; 61:3689-97.
42. + T cells. J Surg Oncol 1998; 67:221-7.
43. Mills KHG, Conroy H, Galvin K, Marshall N. Regulatory T cells in cancer and their suppression as a strategy to enhance the efficacy of immunotherapeutics and vaccines, European Congress of Immunology, Berlin. European Journal of Immunology 2009; 39:565.
44. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. N Engl J Med.
45. Rosenberg SA, Dudley ME. Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc Natl Acad Sci USA 2004; 101:14639-45.
46. Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C, et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the premetastatic niche. Nature 2005; 438:820-7.
47. Luzzi KJ, MacDonald IC, Schmidt EE, Kerkvliet N, Morris VL, Chambers AF, et al. Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. Am J Pathol 1998; 153:865-73.
48. Diener KR, Lousberg EL, Beukema EL, Yu A, Howley PM, Brown MP, et al. Recombinant fowlpox virus elicits transient cytotoxic T cell responses due to suboptimal innate recognition and recruitment of T cell help. Vaccine 2008; 26:3566-73.
49. Finkelstein SE, Heimann DM, Klebanoff CA, Antony PA, Gattinoni L, Hinrichs CS, et al. Bedside to bench and back again: how animal models are guiding the development of new immunotherapies for cancer. J Leukoc Biol 2004; 76:333-7.
50. + T cells traffic indiscriminately and ubiquitously while mediating specific tumor destruction. J Immunol 2004; 173:7209-16.
51. + T cell expansion and function. J Exp Med 2005; 201:139-48.
52. Weisberg E, Manley PW, Cowan-Jacob SW, Hochhaus A, Griffin JD. Second generation inhibitors of BC-RABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer 2007; 7:345-56. (Pubitemid 46652483)
53. You JS, Kang JK, Seo DW, Park JH, Park JW, Lee JC, et al. Depletion of embryonic stem cell signature by histone deacetylase inhibitor in NCCIT cells: involvement of Nanog suppression. Cancer Res 2009; 69:5716-25.
54. Price JE. Clonogenicity and experimental metastatic potential of spontaneous mouse mammary neoplasms. J Natl Cancer Inst 1986; 77:529-35.
55. Zhang G, He B, Weber GF. Growth factor signaling induces metastasis genes in transformed cells: molecular connection between Akt kinase and osteopontin in breast cancer. Mol Cell Biol 2003; 23:6507-19.
56. Zhang RD, Fidler IJ, Price JE. Relative malignant potential of human breast carcinoma cell lines established from pleural effusions and a brain metastasis. Invasion Metastasis 1991; 11:204-15.
57. Noritake H, Miyamori H, Goto C, Seiki M, Sato H. Overexpression of tissue inhibitor of matrix metalloproteinases-1 (TIMP-1) in metastatic MDCK cells transformed by v-src. Clin Exp Metastasis 1999; 17:105-10.
58. Ho LL, Chen WJ, Lin-Shiau SY, Lin JK. Penta-Ogalloyl-beta-D-glucose inhibits the invasion of mouse melanoma by suppressing metalloproteinase-9 through downregulation of activator protein-1. Eur J Pharmacol 2002; 453:149-58.
59. Salo T, Liotta LA, Tryggvason K. Purification and characterization of a murine basement membrane collagendegrading enzyme secreted by metastatic tumor cells. J Biol Chem 1983; 258:3058-63.
60. Cohen DM. SRC family kinases in cell volume regulation. Am J Physiol Cell Physiol 2005; 288:483-93.
61. Nishizumi H, Horikawa K, Mlinaric-Rascan I, Yamamoto T. A double-edged kinase Lyn: a positive and negative regulator for antigen receptor-mediated signals. J Exp Med 1998; 187:1343-8.
62. Scapini P, Pereira S, Zhang H, Lowell CA. Multiple roles of Lyn kinase in myeloid cell signaling and function. Immunol Rev 2009; 228:23-40.
63. Xu Y, Harder KW, Huntington ND, Hibbs ML, Tarlinton DM. Lyn tyrosine kinase: accentuating the positive and the negative. Immunity 2005; 22:9-18. (Pubitemid 40143447)
64. Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion and metastasis. Cell 2006; 124:263-6.
65. Vandyke K, Dewar AL, Farrugia AN, Fitter S, Bik To L, Hughes TP, et al. Therapeutic concentrations of dasatinib inhibit in vitro osteoclastogenesis. Leukemia 2009; 23:994-7.
66. Liang W, Kujawski M, Wu J, Lu J, Herrmann A, Loera S, et al. Antitumor activity of targeting SRC kinases in endothelial and myeloid cell compartments of the tumor microenvironment. Clin Cancer Res 16:924-35.
67. Zhong H, Bowen JP. Molecular design and clinical development of VEGFR kinase inhibitors. Curr Top Med Chem 2007; 7:1379-93.
68. Johnson FM, Saigal B, Talpaz M, Donato NJ. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Clin Cancer Res 2005; 11:6924-32.
69. Coluccia AM, Cirulli T, Neri P, Mangieri D, Colanardi MC, Gnoni A, et al. Validation of PDGFRbeta and c-Src tyrosine kinases as tumor/vessel targets in patients with multiple myeloma: preclinical efficacy of the novel, orally available inhibitor dasatinib. Blood 2008; 112:1346-56.
70. Kim MP, Park SI, Kopetz S, Gallick GE. Src family kinases as mediators of endothelial permeability: effects on inflammation and metastasis. Cell Tissue Res 2009; 335:249-59.
71. Summy JM, Trevino JG, Lesslie DP, Baker CH, Shakespeare WC, Wang Y, et al. AP23846, a novel and highly potent Src family kinase inhibitor, reduces vascular endothelial growth factor and interleukin-8 expression in human solid tumor cell lines and abrogates downstream angiogenic processes. Mol Cancer Ther 2005; 4:1900-11.
72. Chen Z, Lee FY, Bhalla KN, Wu J. Potent inhibition of platelet-derived growth factor-induced responses in vascular smooth muscle cells by BMS-354825 (dasatinib). Mol Pharmacol 2006; 69:1527-33.
73. Weis SM, Cheresh DA. Pathophysiological consequences of VEGF-induced vascular permeability. Nature 2005; 437:497-504.
74. Criscuoli ML, Nguyen M, Eliceiri BP. Tumor metastasis but not tumor growth is dependent on Src-mediated vascular permeability. Blood 2005; 105:1508-14. (Pubitemid 40223667)
75. Eliceiri BP, Paul R, Schwartzberg PL, Hood JD, Leng J, Cheresh DA. Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. Mol Cell 1999; 4:915-24.
76. Rice J, Ottensmeier CH, Stevenson FK. DNA vaccines: precision tools for activating effective immunity against cancer. Nat Rev Cancer 2008; 8:108-20.
77. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004; 10:909-15.
78. Gray A, Raff AB, Chiriva-Internati M, Chen SY, Kast WM. A paradigm shift in therapeutic vaccination of cancer patients: the need to apply therapeutic vaccination strategies in the preventive setting. Immunol Rev 2008; 222:316-27.
79. Kennedy R, Celis E. T helper lymphocytes rescue CTL from activation-induced cell death. J Immunol 2006; 177:2862-72.
80. + T cells in anti-tumor immune responses. Immunol Rev 2008; 222:129-44.
81. Turk MJ, Guevara-Patino JA, Rizzuto GA, Engelhorn ME, Sakaguchi S, Houghton AN. Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J Exp Med 2004; 200:771-82.
82. Kim LC, Rix U, Haura EB. Dasatinib in solid tumors. Expert Opin Investig Drugs 19:415-25.
83. Kluger HM, Dudek A, McCann C, Rink L, Ritacco J, Adrada C, et al. A phase II trial of dasatinib in advanced melanoma, Orlando FL. J Clin Oncol (Meeting Abstracts) 2009; 27:9010.